Core Laboratories N.V.

Core Laboratories N.V.

CLB
Core Laboratories N.V.US flagNew York Stock Exchange
13.16
USD
-0.09
- -
606.63MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23.8
24.87
18.82
13.37
14.66
15.81
15.03
10.93
10.15
10.5
10.88
11.19
11.42
11.47
Basic EPS, GAAP
5.38
5.9
2.71
1.45
1.88
1.79
2.29
-2.19
0.43
0.42
0.78
0.67
0.64
0.63
Free Cash Flow per Basic Share
6.53
6.93
5.14
2.98
2.8
2.5
2.01
1.29
0.78
0.53
0.53
1.2
0.8
0.75
Dividend per Share
1.3
2.04
2.22
2.15
2.2
2.19
2.19
0.28
0.04
0.04
0.04
0.04
0.04
0.04
Book Value per Share
9.25
9.56
5.2
4.28
3.96
3.55
3.64
1.16
1.5
1.87
2.59
3.1
3.76
3.76
Tangible Book Value per Share
-0.11
-1.86
-5
-0.76
-0.9
-1.61
-1.1
-0.73
1.15
1.76
2.63
3.13
3.46
3.55
Basic Weighted Avg Shares
45
44
42
44
44
44
44
45
46
47
47
47
46
46
Sales/Revenue/Turnover
1,074
1,085
798
590
648
701
668
487
470
490
510
524
527
525
Operating Margin (%)
31.03
32.03
23.53
14.75
17.07
16.82
15.49
12.13
8.5
8.44
11.02
9.5
9.59
8.57
Depreciation Expense
25
27
27
27
25
23
23
21
19
17
16
15
15
15
Net Income, GAAP
243
257
115
64
83
80
102
-98
20
19
37
31
30
29
Effective Tax Rate (%)
24.96
23.01
22.7
14.31
18.39
24.17
- -
- -
44.01
34.37
10.16
30.39
33.78
31.36
Profit Margin (%)
22.62
23.73
14.4
10.83
12.83
11.35
15.26
-20.04
4.19
3.97
7.19
5.99
5.63
5.53
Working Capital
168
170
118
82
107
128
110
76
98
109
135
119
109
110
LT Debt
267
354
431
216
227
290
370
316
238
211
205
169
153
156
Total Equity
169
94
-24
155
149
161
182
76
161
189
230
252
272
275
Return on Invested Capital (%)
55.87
58.25
33.04
18.54
23.4
21.29
- -
- -
5.37
6.48
11.57
7.68
7.56
6.93
Return on Capital (%)
38.6
36.05
17.34
13.85
22.54
20.85
- -
- -
6.89
8.41
14.76
11.67
10.66
10.54
Return on Common Equity (%)
62.29
61.73
36.03
31.21
45.66
47.87
63.95
-91.55
32.57
24.83
35.2
23.56
18.63
18.03

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
11
11
12
LT Borrowings
114
110
114
LT Finance Leases
42
42
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
575
736
768

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
227
215
214
Cash, Cash Equivalents & STI
26
23
23
Accounts Receivable, Net
110
114
108
Inventories
58
54
58
Total Current Liabilities
96
106
105
Payables & Accruals
68
72
71
ST Debt
11
11
12
Deferred Revenue
7
6
5

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-62.7%
33.94%
7.88%
Free Cash Flow
-8.66%
4.91%
-34.33%
Net Income, GAAP
-23.9%
-10.59%
-5.51%
Sales/Revenue/Turnover
-3.18%
1.6%
0.51%
Total Cash Common Dividend
-16.71%
-16.67%
-0.37%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
130
131
134
129
524
2025
124
130
135
138
527
2026
122
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.19
0.25
0.16
0.67
2025
- -
0.23
0.31
0.11
0.64
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
0.01
0.01
0.04
2026
0.01
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Lawrence V. Bruno
Full Time Employees
3,400
Sector
Energy
Industry
Oil & Gas Equipment & Services
Address
6316 Windfern Road Houston TX United States of America 77040
IPO Date
Sep 21, 1995
Business
Core Laboratories N.V. (NYSE: CLB) provides proprietary and patented reservoir description, production enhancement, and reservoir management services and products to the oil and gas industry worldwide. The company offers core analysis including basic rock properties, special core analysis, digital rock characterization, and non-invasive technologies such as NITRO SM for rapid Fit-For-Reservoir TM core and fluid data; reservoir fluid characterization and PVT analysis; production enhancement solutions encompassing proppant crush testing with Complete Crush TM, hydraulic fracturing diagnostics, production logging, well spacing diagnostics using tracers, and enhanced oil recovery studies; petroleum products testing and crude oil assays; carbon capture and storage subsurface characterization; laboratory instruments, pumps, and accessories; as well as reservoir modeling, simulation, and field development planning. Core Laboratories operates through three segments—Reservoir Description, Production Enhancement, and Reservoir Management—serving major, national, and independent oil companies across more than 50 countries on six continents with over 70 offices and four advanced technology centers. Founded in 1936 with roots in Dallas, Texas, and headquartered in Houston, Texas, the company, incorporated as a Netherlands limited liability company, maintains approximately 3,200 employees. In 2025, Core Laboratories completed the acquisition of Brazil-based Solintec, an integrated geological services provider, for an initial $2.3 million plus potential earnout of up to $3.7 million to expand in-country capabilities for pre-salt offshore and onshore projects along the South Atlantic Margin.

Company News

MCPAPIChat
  • Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?

  • Arista Introduces Next-Generation 1.6Terabit Portfolio for AI Fabrics

  • Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?

  • Implied Volatility Surging for Core Laboratories Stock Options

  • Core Laboratories Q1 Earnings Meet Estimates, Decline Y/Y

  • Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript

  • CORE LAB REPORTS FIRST QUARTER 2026 RESULTS

  • DTI or CLB: Which Is the Better Value Stock Right Now?

  • Core Laboratories to Post Q1 Earnings: Key Metrics to Watch

  • Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline

  • DTI vs. CLB: Which Stock Is the Better Value Option?

  • DTI vs. CLB: Which Stock Should Value Investors Buy Now?

  • Middle East Conflict Weighs On Core Laboratories' Q1 Outlook

  • Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now

  • CORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCE

  • Core Laboratories (NYSE:CLB) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

  • DTI or CLB: Which Is the Better Value Stock Right Now?

  • Why Is Core Laboratories (CLB) Down 14.2% Since Last Earnings Report?

  • Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?

  • Core Laboratories Q4 Earnings Call Highlights